We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Part of the pillar guide: Peptide Therapy — Complete Guide

kindr
Melanocortin Receptor Agonist · FDA-Approved for Women

Low libido is not a character flaw. It is neurology. PT-141 addresses it.

PT-141 (Bremelanotide) works centrally — activating melanocortin receptors in the brain to increase sexual desire directly. Unlike medications that increase blood flow, PT-141 addresses desire at the neurological level. The only peptide FDA-approved for sexual dysfunction in women.

Request Physician Evaluation →
· Physician evaluation required· Licensed 503A pharmacy· All 50 US states
FDA 2019
Year Bremelanotide (Vyleesi) approved for HSDD in premenopausal women
Central
Mechanism — works in the brain, not peripherally like PDE5 inhibitors
Both
Used for women and men — FDA-approved for women, off-label for men

How PT-141 works differently from everything else.

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist — it activates MC3R and MC4R receptors in the central nervous system. This is fundamentally different from how most sexual health medications work. Sildenafil (Viagra) and similar drugs increase genital blood flow — they address the physical mechanism but not desire itself. PT-141 works upstream, activating the brain pathways that generate sexual desire.

Low libido in women — particularly during perimenopause and menopause — is driven by both hormonal changes (estrogen, testosterone decline) and neurological changes. HRT addresses the hormonal dimension. PT-141 addresses the neurological dimension. Many women benefit from both — used together they address the full picture of desire loss during hormonal transition.

PT-141 is used off-label for men — particularly those with psychogenic ED (desire-related rather than vascular) or men who do not respond adequately to PDE5 inhibitors. It works through a completely different mechanism than Viagra or Cialis and can be used alone or in combination.

PT-141 — Central mechanism
Activates melanocortin receptors (MC3R/MC4R) in the hypothalamus. Directly increases sexual motivation and desire at the neurological level. Effect begins 45 minutes to 1 hour after administration and lasts 6-12 hours.
Vs. PDE5 Inhibitors (Viagra/Cialis)
Inhibit PDE5 enzyme to increase genital blood flow. Work peripherally — address physical arousal response but do not directly affect desire or motivation. Require physical stimulation to be effective.

The clinical record.

Bremelanotide (Vyleesi) received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is one of only two FDA-approved medications for sexual dysfunction in women.
25%
Increase in satisfying sexual events vs placebo in the RECONNECT trial — the pivotal FDA approval trial.
35%
Women in RECONNECT reported meaningful improvement in sexual desire on the Female Sexual Function Index (FSFI) desire subscale vs placebo.
Menopause gap
The FDA approved Vyleesi for premenopausal women. Women in menopause — who have even greater prevalence of HSDD — use it off-label through physician evaluation.
Off-label men
PT-141 is used off-label for male sexual dysfunction — particularly desire-related and psychogenic ED. No FDA approval for men but established clinical use.

Compounded PT-141 is not the same as FDA-approved Vyleesi. Data above reflects FDA-approved bremelanotide clinical trials.

Who PT-141 is prescribed for.

Women in menopause with low libido
Estrogen and testosterone decline during menopause directly reduce sexual desire. HRT addresses hormonal contributors. PT-141 addresses the neurological dimension — making the combination of HRT and PT-141 more comprehensive than either alone.
Women with HSDD (all ages)
Hypoactive sexual desire disorder is the most common female sexual dysfunction — affecting an estimated 10% of women. PT-141 is the only FDA-approved treatment for HSDD in premenopausal women.
Men with desire-related ED
Not all ED is vascular. Psychogenic or desire-related ED does not respond to PDE5 inhibitors the way vascular ED does. PT-141 works centrally and represents a different approach for men where desire — not blood flow — is the primary factor.
GLP-1 users experiencing reduced libido
Hormonal shifts during rapid weight loss on GLP-1 medications can reduce libido in some women. PT-141 can address this specific presentation.
Contraindications
  • Known cardiovascular disease
  • Uncontrolled hypertension
  • Current use of naltrexone
  • Pregnancy or breastfeeding
  • Hypersensitivity to melanocortin agonists

Administration

Subcutaneous injection administered 45-60 minutes before anticipated sexual activity. Used on-demand — not daily. Your physician will determine appropriate dosing protocol.

Common side effects

  • Nausea — most common (40% in trials)
  • Flushing (warmth/redness)
  • Headache
  • Injection site reactions
  • Fatigue
  • Hyperpigmentation (with repeated use)
Note on nausea. Nausea is the most common side effect and the primary reason for discontinuation in clinical trials. It typically peaks 1 hour after administration and resolves within a few hours. Anti-nausea medication may be recommended for patients who experience significant nausea.
Blood pressure. PT-141 can transiently decrease blood pressure. Patients with cardiovascular conditions should not use PT-141. Your physician will screen for cardiovascular risk factors during evaluation.

Request your PT-141 evaluation.

Complete this form to be evaluated for compounded PT-141. A licensed physician will review your submission within 24 hours.

Compounded PT-141 is not FDA-approved. Only Vyleesi is FDA-approved (for premenopausal HSDD). Use in menopausal women and men is off-label. Clinical services by Arora Health & Aesthetics LLC. Compounded by VialsRX. Prescription not guaranteed.

Frequently asked questions.

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist. It activates MC3R and MC4R receptors in the central nervous system to increase sexual desire directly. The FDA-approved version (Vyleesi) was approved in 2019 for hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 is available through physician evaluation for both women and men.

Sexual desire starts in the brain. So does the solution.

Request Physician Evaluation →
FDA-approved for HSDD in premenopausal women (Vyleesi). Off-label for menopausal women and men. Compounded PT-141 is not FDA-approved. Clinical services by Arora Health & Aesthetics LLC. Compounded by VialsRX, Houston TX — 503A.
Related kindr resources

Keep reading

kindr Libido Revive
Daily supplement protocol for libido and sexual wellness.
Read kindr Libido Revive →
Hormone therapy
Address the hormonal drivers of low libido at the source.
Read Hormone therapy →
Men's health
Comprehensive men's sexual wellness and TRT options.
Read Men's health →

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026

Latest from the Journal

Ask Dot